Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide/G-CSF Priming for Autologous SCT in CML
NCT00005984Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Aug 2000
- Primary completion
- Sep 2005
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, filgrastim in chronic myelogenous leukemia (CML), sponsored by Masonic Cancer Center. Started Aug 2000; status: terminated.
02
Drugs
cyclophosphamidefilgrastim
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00005984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005984.